Clinical trials: Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
This phase Ib/II trial studies the side effects and best dose of ribociclib, tucatinib, and trastuzumab for the treatment of HER2 positive breast cancer that has spread to other parts of the body (metastatic), and then compares…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT05319873
- Testing
- Carboplatin, Docetaxel, Fulvestrant
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Neoplasms
Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer
RATIONALE: Educational programs may improve coping and quality of life in younger women who have recently been treated for early-stage breast cancer.
- Trial name
- NCT00416572
- Testing
- Education Intervention, Nutrition Education Intervention
- Volunteers
- 252 people
- Sponsor
- Carnegie Mellon University
Breast Cancer, Cardiovascular Complications
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving bevacizumab may help doctors learn more about changes that occur in DNA and identify biomarkers related to high blood pressure.
- Conditions
- Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01096381
- Testing
- laboratory biomarker analysis, questionnaire administration
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by reducing the production of estrogen.
- Trial name
- NCT00032136
- Testing
- exemestane, tamoxifen citrate, adjuvant therapy
- Where
- United Kingdom
- Volunteers
- 4,400 people
- Sponsor
- Cancer Research Campaign Clinical Trials Centre
Breast Cancer
Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer
RATIONALE: Ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cancer cell growth. Studying samples of blood and tissue from patients with breast cancer in the laboratory may help doctors learn…
- Trial name
- NCT01009437
- Testing
- ritonavir, therapeutic conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer
This clinical trial evaluates the feasibility of exercise during chemotherapy in older women with stage I-III breast cancer. Previous studies have reported that exercise may reduce the chemotherapy-toxicity risk.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT05025059
- Testing
- Discussion, Exercise Intervention, Informational Intervention
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Radiation Therapy in Treating Women With Early Stage Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells. Giving it after surgery may kill any tumor cells that remain after surgery.
- Trial name
- NCT00909909
- Testing
- External beam boost, whole breast irradiation
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer
Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women
RATIONALE: Studying mammograms for breast density changes over time may help doctors predict breast cancer risk. PURPOSE: This natural history study is looking at changes in breast density and gathering health information over…
- Trial name
- NCT00445445
- Testing
- physiologic testing, screening questionnaire administration, breast imaging study
- Where
- 8 sites in United States
- Volunteers
- 2,201 people, healthy volunteers welcome
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
Self-Care for Lymphedema in Patients With Breast Cancer
RATIONALE: Identifying why patients don't do self care for lymphedema may help doctors plan better at-home self-care treatment. PURPOSE: This research study is looking at self-care practices for lymphedema in patients with breast…
- Trial name
- NCT00670644
- Testing
- questionnaire administration, survey administration, quality-of-life assessment
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- Vanderbilt University
Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma
Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer
This phase II trial studies how well hypofractionated partial breast irradiation works in treating patients with early stage breast cancer.
- Conditions
- Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7
- Trial name
- NCT03077841
- Testing
- Laboratory Biomarker Analysis, Partial Breast Irradiation, Questionnaire Administration
- Where
- 15 sites in United States
- Volunteers
- 928 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00072319
- Testing
- filgrastim, cyclophosphamide, epirubicin hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
This phase I trial studies the effects (good and bad) of adding copanlisib to the usual therapy of fulvestrant and abemaciclib in treating patients with hormone receptor positive and HER2 negative breast cancer that has spread…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
- Trial name
- NCT03939897
- Testing
- Abemaciclib, Biopsy Procedure, Biospecimen Collection
- Where
- 14 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence
RATIONALE: Vaccines may make the body build an immune response and decrease the recurrence of breast cancer. PURPOSE: Pilot trial to study the effectiveness of vaccine therapy in treating patients who are at high risk for breast…
- Trial name
- NCT00030823
- Testing
- Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine, QS21
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer
This phase II trial studies how well rifaximin works for the treatment of gastrointestinal toxicities related to pertuzumab-based therapy in patients with stage I-III HER2 positive breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04249622
- Testing
- Best Practice, Questionnaire Administration, Rifaximin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Breast Cancer
Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease
RATIONALE: Vaccines made from GM2-KLH and given with QS21 may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of GM2-KLH vaccine plus QS21 in treating patients…
- Trial name
- NCT00003357
- Testing
- GM2-KLH vaccine, QS21
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Stage III Breast Cancer
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
This research is being done to assess whether an exercise intervention with protein intake support vs a health education and support program will make it easier for women age 65 or older who are receiving chemotherapy for breast…
- Conditions
- Breast Cancer, Stage III Breast Cancer, Breast Cancer Female, Stage I Breast Cancer
- Trial name
- THRIVE-65 (NCT05535192)
- Testing
- THRIVE, Health Education Support Program
- Where
- 4 sites in United States
- Volunteers
- 270 people
- Sponsor
- Dana-Farber Cancer Institute
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
This phase II trial tests whether fisetin works to improve physical function in women who have received chemotherapy for stage I-III breast cancer treatment.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT05595499
- Testing
- Biospecimen Collection, Fisetin, Quality-of-Life Assessment
- Where
- 7 sites in United States
- Volunteers
- 88 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
- Trial name
- NCT06876714
- Testing
- Trastuzumab (Herceptin), Pertuzumab, Echocardiography
- Where
- 702 sites in United States, Puerto Rico
- Volunteers
- 1,524 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Chemotherapeutic Agent Toxicity
G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer
RATIONALE: G-CSF may prevent or reduce febrile neutropenia in women receiving chemotherapy for breast cancer. It is not yet known which G-CSF regimen is more effective in preventing neutropenia.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Neutropenia
- Trial name
- NCT00771433
- Testing
- filgrastim
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Francois Baclesse
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
This phase I/II trial studies the side effects and best dose of copanlisib and how well it works when given together with eribulin in treating patients with triple negative breast cancer that has spread from where it first…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
- Trial name
- NCT04345913
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 43 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)